Vaxcyte (PCVX) to Release Earnings on Tuesday

Key Points

• Vaxcyte is expected to announce its Q2 2025 earnings on August 5th, with analysts projecting a loss of ($1.12) per share for the quarter.
• The company has recently missed earnings estimates, reporting a loss of ($1.04) per share in its last quarter compared to an expected ($1.02).
• Vaxcyte's stock is currently rated as a "buy" by nine analysts, with a consensus price target of $136.50.

Vaxcyte (NASDAQ:PCVX - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($1.12) per share for the quarter.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the previous year, the business earned ($0.85) earnings per share. On average, analysts expect Vaxcyte to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vaxcyte Stock Performance

Vaxcyte stock traded down $0.84 during midday trading on Friday, reaching $33.11. The company's stock had a trading volume of 648,341 shares, compared to its average volume of 1,796,984. Vaxcyte has a fifty-two week low of $27.66 and a fifty-two week high of $121.06. The stock's 50 day simple moving average is $34.43 and its 200 day simple moving average is $50.89. The firm has a market capitalization of $4.27 billion, a PE ratio of -8.31 and a beta of 1.19.

Analyst Ratings Changes

A number of research firms have commented on PCVX. Cantor Fitzgerald began coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Needham & Company LLC reissued a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Vaxcyte currently has a consensus rating of "Buy" and a consensus target price of $136.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PCVX. Royal Bank of Canada raised its stake in shares of Vaxcyte by 115.2% during the 1st quarter. Royal Bank of Canada now owns 29,471 shares of the company's stock worth $1,113,000 after buying an additional 15,774 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Vaxcyte during the 1st quarter worth $219,000. Caxton Associates LLP acquired a new position in shares of Vaxcyte during the 1st quarter worth $226,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Vaxcyte by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company's stock worth $19,409,000 after buying an additional 41,034 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.